Effects of dose on psilocybin mystical experiences and ‘bad trips’ | Roland Griffiths
Get the full length version of this episode as a podcast.
This episode will make a great companion for a long drive.
The BDNF Protocol Guide
An essential checklist for cognitive longevity — filled with specific exercise, heat stress, and omega-3 protocols for boosting BDNF. Enter your email, and we'll deliver it straight to your inbox.
Dr. Roland Griffiths is a clinical pharmacologist at Johns Hopkins and one of the world's foremost researchers on the psychedelic compound psilocybin.
This transcript is reserved for members.
FoundMyFitness Members get access to exclusive content not available anywhere else, including a transcript of this episode.
You wouldn't believe how cool being a premium member of the world's best cross-disciplinary science-focused website and podcast really is.
A naturally occurring psychedelic compound produced by more than 200 species of mushrooms. As a prodrug, psilocybin is quickly converted by the body to psilocin, which has mind-altering effects including euphoria, visual and mental hallucinations, changes in perception, a distorted sense of time, and spiritual experiences, and can include possible adverse reactions such as nausea and panic attacks.
Member only extras:
Learn more about the advantages of a premium membership by clicking below.
Attend Monthly Q&As with Rhonda
Support our work
The FoundMyFitness Q&A happens monthly for premium members. Attend live or listen in our exclusive member-only podcast The Aliquot.
Psychedelic News
- Depression symptoms dropped markedly after one 25-milligram psilocybin dose in a study of people with severe treatment-resistant depression.
- Psilocybin from 'magic' mushrooms offers comparable or enhanced depression relief over traditional SSRIs, improving social functioning and life meaning.
- Older adults who used psychedelics exhibited better cognitive function and fewer depressive symptoms than non-users.
- Psilocybin reduces symptoms of depression, especially among people with secondary depression.
- Psychobiotics and the Microbiota–Gut–Brain Axis: Where Do We Go from Here?
